Prostate Cancer

The FDA has approved abiraterone acetate in combination with prednisone prior to chemotherapy for the treatment of men with metastatic castration-resistant prostate cancer.

Single-agent cabozantinib has shown promising activity in early-stage trials involving heavily pretreated patients with metastatic castration-resistant prostate cancer. Researchers are now attempting to find the optimal dose of the drug in this patient population.

Mary-Ellen Taplin, MD, from the Dana-Farber Cancer Institute, discusses unique mechanism of action of enzalutamide in metastatic castration-resistant prostate cancer.

Enzalutamide significantly delayed the time to first SRE and significantly improved pain and QOL compared with placebo in men with mCRPC who had received prior docetaxel.

A research team has discovered 12 genetic markers associated with the development of erectile dysfunction in prostate cancer patients treated with radiation.

A deeper understanding of androgen receptor signaling in castration-resistant prostate cancer has created an opportunity to deliver more effective therapies earlier in the treatment timeline.

William K. Oh, MD, from the Tisch Cancer Institute, discusses strategies for sequencing the new therapies that have been approved for treating castration-resistant prostate cancer.

Men who take the dietary antioxidant beta-carotene while they are undergoing radiation therapy for prostate cancer do not have an increased risk of prostate cancer death or metastases.

Michael Rotkowitz, MD, says that one of the main challenges and a leading goal of immunotherapy research is measuring response to justify the administration.

Stephen J. Freedland, MD, from Duke University School of Medicine, discusses the complications faced when treating men with early-stage prostate cancer.

Men with increased cholesterol levels may have an elevated risk of developing high-grade prostate cancer.

Patients who received sipuleucel-T developed immune parameters that correlated with improved overall survival suggesting that these parameters should be the focus of further studies on the treatment.

A novel assay could determine when patients with metastatic prostate cancer begin to relapse on androgen deprivation therapy, and which patients may respond better to second-line therapies.

Daniel R. Saltzstein, MD, describes steps Urology San Antonio has taken toward creation of a comprehensive urologic care practice, including establishment of a bone health clinic and an advanced prostate cancer clinic.

James Mohler, MD, from Roswell Park Cancer Institute, discusses androgen-deprivation therapy, a standard treatment for men with metastatic prostate cancer.

Daniel P. Petrylak, MD, from the Smilow Cancer Center, discusses the recent approval and future role of enzalutamide for patients with prostate cancer.

Novel formulations of specialty drugs have shifted the treatment of patients taking oncologic and biologic agents from infusion centers to the doctor's office.

In April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.

Abiraterone acetate significantly improved overall survival with positive responses seen in several subgroups of patients with metastatic castration-resistant prostate cancer.

A quick glance at a recent study examining the renal cell carcinoma immunotherapy AGS-003 and the FDA approval of a new noninvasive prostate health index test.

Dr. Daniel Petrylak, from the Smilow Cancer Center at Yale-New Haven, Explains the Correlation Between Immune Response to Sipuleucel-T and Survival.

Targeted focal therapy offers some men with localized prostate cancer a solution between active surveillance and definitive treatment with surgery and/or radiation.

The FDA approved enzalutamide for use in patients with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel and hormonal therapy.

Dr. James Mohler, from Roswell Park Cancer Institute, Discusses the Need for Intermediate Endpoints for Early Stage Prostate Cancer Trials.

The FDA announced that Priority Review has been granted to abiraterone acetate for certain advanced prostate cancer cases based on positive data presented at the ASCO annual meeting.